

Clinical site
Tumour
Preconditioning chemotherapy
TIL returned with IL2 support
TIL outgrowth
Rapid Expansion Protocol
Final product
Manufacturing site

Fig. 1




Lymphocytes
39.71%-T
39.71%-#
SSCA
FSC-A
Single cells
37.85%-T
95.30%-#
FSC-H
FSC-A
Live cells
35.72%-T
94.39%-#
Live-dead-A
FSC-A
0.81%-T
0.04%-#
35.57%-T
99.56%-#
0.08%-T
0.22%-#
CD62L-A
CD45RO-A
10.63%-#
82.56%-#
CD4-A
CD8-A
Naive cells
0.00%-T
0.00%-#
0.01%-T
100.00%-#
CD4-A
CD8-A
CD4+
92.15%-#6.73%-#
98.88%-#
6.73%-#
1.12%-#0.00%-#
SLAM-A
GITR-A
CD8+
95.45%-#2.98%-#
98.44%-#
2.98%-#
1.56%-#0.00%-#
SLAM-A
GITR-A
Memory cells
3.80%-T
10.67%-#
29.40%-T
82.66%-#
CD4-A
CD8-A
CD4+
88.04%-#
10.65%-#
98.69%-#
10.84%-#
1.12%-#
0.19%-#
SLAM-A
GITR-A
Effector cells
0.00%-T
0.00%-#
0.02%-T
27.27%-#
CD4-A
CD8-A
CD8+
93.19%-#
4.92%-#
98.12%-#
4.92%-#
1.88%-#
0.00%-#
SLAM-A
GITR-A


Fig. 2




Mean ± SEM

Significance determined using 2-way ANOVA, followed by Sidak's multiple comparison test

Memory: PD vs R, **p = 0.009



Mean ± SEM



Mean ± SEM

Significance determined using 2-way ANOVA, followed by Sidak's multiple comparison test

CD4: PD vs SD, *p = 0.037; PD vs R, **p = 0.004

CD8: PD vs R, **p = 0.008

Fig. 3a





A
% SLAM+ cells
CD4+ pre
CD4+ post
CD8+ pre
CD8+ post
B
% SLAM+ cells
CD4+ N pre
CD4+ N post
CD4+ M pre
CD4+ M post
CD4+ E pre
CD4+ E post
C
% SLAM+ cells
CD8+ N pre
CD8+ N post
CD8+ M pre
CD8+ M post
CD8+ E pre
CD8+ E post
D
%SLAM+cells
CD4+
CD8+
• Progressive Disease
▵ Stable Disease
▫ Responders
E
CD4+
%SLAM+cells
Naive
Memory
Effector
F
CD8+
%SLAM+cells
Naive
Memory
Effector

Fig. 3b



Median = 2.4 v 21.3 months
p- = 0.009 (Wilcoxon)
Plateau = 44%



Median = 4 v NR months
p- = 0.027 (Wilcoxon)
Plateau = 55%

Fig. 4



TIL Alone
Viability (%)
80
60
40
20
0
Unsorted
SLAM Low
SLAM High
Unsorted
SLAM Low
SLAM High
TIL032
TIL054
TIL + Tumour
Viability (%)
60
40
20
0
Unsorted
SLAM Low
SLAM High
Unsorted
SLAM Low
SLAM High
TIL032
TIL054

Fig. 5A



TIL032 CD4+ (no tumour)
TIL032 CD4+ (+ tumour)
TIL032 CD8+ (no tumour)
TIL032 CD8+ (+ tumour)
TIL054 CD4+ (no tumour)
TIL054 CD4+ (+ tumour)
TIL054 CD8+ (no tumour)
TIL054 CD8+ (+ tumour)
% cytokine +
IFNg
IL-2
TNFa
Unsorted
SLAM Low
SLAM High

Fig. 5B



qPCR analysis of SLAMF1 after 76h
Relative SLAMF1 Gene Expression
0.010
0.008
0.006
0.004
0.0004
0.0003
0.0002
0.0001
0.0000
-0.0001
control
siRNA
control
siRNA
control
siRNA
Raji
MRIBB011
TIL032

Fig. 6A



Raji
MRIBB011
TIL032
Control
SLAMf1 siRNA
18-08-10.0055_ _ _\P3
18-08-10.0058_ _ _\P3
18-08-10.0061_ _ _\P3
18-08-10.0054_ _ _\P3
18-08-10.0057_ _ _\P3
18-08-10.0060_ _ _\P3
SLAM+
89.65%
82.46%
99.54%
84.90%
65.34%
89.96%
FSC-A
SLAMf1 PF-A

Fig. 6B



A)
EF1α
SLAM
2A
tCD19
B)
CD19+/SLAM+
80
60
40
20
0
0
6.25
12.5
25
50
100
% virus

Fig. 7